Biopharmaceutical company Gilead Sciences gained on news that a JPMorgan analyst, Geoff Meacham, had positive comments about some of its drug treatments. Morningstar reported that Meacham cited both Stribild, a treatment for AIDS, and its hepatitis C drug program. JPMorgan raised its target price to $75 per share, from $70, Morningstar said.